The role of the TLR9 pathway in anticancer treatment has been considered in animal models and patients with renal carcinoma, malignant melanoma, and non-Hodgkin’s lymphoma [27–31]. The gene discussed is TLR9; the disease is non-Hodgkin lymphoma.